One-year follow-up of COVID-19 recoverees with impaired pulmonary function: A prospective cohort study

Nitzan Karny Epstein; Dana Yelin; Dorit Shitenberg; Dafna Yahav; Leonard Leibovici; Vered Daitch; Ili Margalit

doi:10.1016/j.idnow.2024.104890

One-year follow-up of COVID-19 recoverees with impaired pulmonary function: A prospective cohort study

Nitzan Karny Epstein^*, Dana Yelin, Dorit Shitenberg, Dafna Yahav, Leonard Leibovici, Vered Daitch, Ili Margalit

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Decreased diffusion capacity for carbon monoxide (DLCO) is the most prevalent pulmonary testing abnormality among COVID-19 recoverees. We prospectively followed 51 individuals with impaired DLCO at an average of ∼3 months following COVID-19 and re-examined them at one year. At follow-up, mean DLCO increased from 68.0 % to 72.6 % (p = 0.002); while 33 % of the cohort experienced a clinically significant rise (>10 points) in DLCO, only 29 % normalized their values. While DLCO change did not correlate with symptoms, lack of improvement was more prevalent among individuals with obesity. Regardless of COVID-19 severity, a substantial proportion continued to exhibit DLCO impairment at 1-year.

Original language	English
Article number	104890
Journal	Infectious Diseases Now
Volume	54
Issue number	3
DOIs	https://doi.org/10.1016/j.idnow.2024.104890
State	Published - Apr 2024

Keywords

DLCO
Dyspnea
Long-COVID
Long-term

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.idnow.2024.104890

Cite this

@article{0380bd368be94a2aaab45a828c3bb2d5,

title = "One-year follow-up of COVID-19 recoverees with impaired pulmonary function: A prospective cohort study",

abstract = "Decreased diffusion capacity for carbon monoxide (DLCO) is the most prevalent pulmonary testing abnormality among COVID-19 recoverees. We prospectively followed 51 individuals with impaired DLCO at an average of ∼3 months following COVID-19 and re-examined them at one year. At follow-up, mean DLCO increased from 68.0 % to 72.6 % (p = 0.002); while 33 % of the cohort experienced a clinically significant rise (>10 points) in DLCO, only 29 % normalized their values. While DLCO change did not correlate with symptoms, lack of improvement was more prevalent among individuals with obesity. Regardless of COVID-19 severity, a substantial proportion continued to exhibit DLCO impairment at 1-year.",

keywords = "DLCO, Dyspnea, Long-COVID, Long-term",

author = "Epstein, {Nitzan Karny} and Dana Yelin and Dorit Shitenberg and Dafna Yahav and Leonard Leibovici and Vered Daitch and Ili Margalit",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Masson SAS",

year = "2024",

month = apr,

doi = "10.1016/j.idnow.2024.104890",

language = "אנגלית",

volume = "54",

journal = "Infectious Diseases Now",

issn = "2666-9927",

publisher = "Elsevier Masson s.r.l.",

number = "3",

}

TY - JOUR

T1 - One-year follow-up of COVID-19 recoverees with impaired pulmonary function

T2 - A prospective cohort study

AU - Epstein, Nitzan Karny

AU - Yelin, Dana

AU - Shitenberg, Dorit

AU - Yahav, Dafna

AU - Leibovici, Leonard

AU - Daitch, Vered

AU - Margalit, Ili

PY - 2024/4

Y1 - 2024/4

N2 - Decreased diffusion capacity for carbon monoxide (DLCO) is the most prevalent pulmonary testing abnormality among COVID-19 recoverees. We prospectively followed 51 individuals with impaired DLCO at an average of ∼3 months following COVID-19 and re-examined them at one year. At follow-up, mean DLCO increased from 68.0 % to 72.6 % (p = 0.002); while 33 % of the cohort experienced a clinically significant rise (>10 points) in DLCO, only 29 % normalized their values. While DLCO change did not correlate with symptoms, lack of improvement was more prevalent among individuals with obesity. Regardless of COVID-19 severity, a substantial proportion continued to exhibit DLCO impairment at 1-year.

AB - Decreased diffusion capacity for carbon monoxide (DLCO) is the most prevalent pulmonary testing abnormality among COVID-19 recoverees. We prospectively followed 51 individuals with impaired DLCO at an average of ∼3 months following COVID-19 and re-examined them at one year. At follow-up, mean DLCO increased from 68.0 % to 72.6 % (p = 0.002); while 33 % of the cohort experienced a clinically significant rise (>10 points) in DLCO, only 29 % normalized their values. While DLCO change did not correlate with symptoms, lack of improvement was more prevalent among individuals with obesity. Regardless of COVID-19 severity, a substantial proportion continued to exhibit DLCO impairment at 1-year.

KW - DLCO

KW - Dyspnea

KW - Long-COVID

KW - Long-term

UR - http://www.scopus.com/inward/record.url?scp=85188426641&partnerID=8YFLogxK

U2 - 10.1016/j.idnow.2024.104890

DO - 10.1016/j.idnow.2024.104890

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 38499177

AN - SCOPUS:85188426641

SN - 2666-9927

VL - 54

JO - Infectious Diseases Now

JF - Infectious Diseases Now

IS - 3

M1 - 104890

ER -

One-year follow-up of COVID-19 recoverees with impaired pulmonary function: A prospective cohort study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this